Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $4.60 Consensus Target Price from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $4.60.

Separately, HC Wainwright reduced their price objective on Karyopharm Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, June 28th.

Karyopharm Therapeutics Trading Down 3.6 %

Shares of Karyopharm Therapeutics stock opened at $0.89 on Monday. The stock has a fifty day simple moving average of $0.95 and a 200 day simple moving average of $1.12. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95. The company has a market capitalization of $110.91 million, a P/E ratio of -0.70 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. The business had revenue of $33.13 million during the quarter, compared to the consensus estimate of $35.02 million. On average, analysts predict that Karyopharm Therapeutics will post -1.16 EPS for the current year.

Insider Activity

In other news, Director Deepika Pakianathan sold 204,394 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $0.95, for a total transaction of $194,174.30. Following the transaction, the director now owns 14,697 shares of the company’s stock, valued at approximately $13,962.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 1,275,473 shares of company stock valued at $1,234,542 in the last 90 days. Insiders own 4.30% of the company’s stock.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its holdings in Karyopharm Therapeutics by 6.5% during the 4th quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after purchasing an additional 108,286 shares in the last quarter. Ikarian Capital LLC lifted its holdings in Karyopharm Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock worth $618,000 after purchasing an additional 9,355 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth about $339,000. Panagora Asset Management Inc. purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth about $197,000. Finally, Monashee Investment Management LLC purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth about $115,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).